RMD Cash & equivalents
Cash & equivalents at ResMed rose to $1.2B in fiscal 2025, the highest in the 5 years reported, from $238M in 2024.
Cash and cash equivalents at year end, as filed.
SOURCE: us-gaap:CashAndCashEquivalentsAtCarryingValue · EDGAR CompanyFacts · CIK 943819 · EDGAR ↗ · FY2021–FY2025 · ANNUAL
FY2025$1.2B
FY2024 $238M
HIGH$1.2B FY2025
LOW$228M FY2023
History AS FILED · DERIVATION SHOWN WHERE DERIVED
| Fiscal year | Cash & equivalents | Change |
|---|---|---|
| FY2025 | $1.2B | +$971M |
| FY2024 | $238M | +$10M |
| FY2023 | $228M | $-46M |
| FY2022 | $274M | $-22M |
| FY2021 | $295M | — |
More SAME DATA, OTHER VIEWS
Cash & equivalents across coverage → · RMD company view →
Revenue · Net income · Operating cash flow · Free cash flow · Capital expenditure · Total assets · Shareholders' equity · Total debt · Return on equity · Days sales outstanding
Not investment advice. Every figure on this page is an XBRL fact from the issuer's own SEC filings or an arithmetic over such facts with the method shown. No forecast is made; no posture is expressed.